Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Plain-language summary
This Phase 2 trial is testing Brentuximab vedotin and Pembrolizumab for people whose anaplastic large cell lymphoma (ALCL) has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 2 US locations.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Brentuximab vedotin (DRUG): Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. | Pembrolizumab (DRUG): Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
- Drugs / treatments
- Brentuximab vedotin, Pembrolizumab
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details